Trials / Completed
CompletedNCT00670189
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-833923 (XL139) | Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2014-04-01
- Completion
- 2014-05-01
- First posted
- 2008-05-01
- Last updated
- 2014-08-15
Locations
3 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00670189. Inclusion in this directory is not an endorsement.